Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1 Multiple Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Subcutaneous CTI-1601 Versus Placebo in Subjects With Friedreich's Ataxia

X
Trial Profile

A Phase 1 Multiple Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Subcutaneous CTI-1601 Versus Placebo in Subjects With Friedreich's Ataxia

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 01 Nov 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Nomlabofusp (Primary)
  • Indications Friedreich's ataxia
  • Focus Adverse reactions; Proof of concept
  • Sponsors Larimar Therapeutics
  • Most Recent Events

    • 19 Oct 2022 According to Larimar Therapeutics media release, the data from phase I clinical program evaluating CTI-1601 for the treatment for Friedreich's Ataxia will be featured in the three presentations at the upcoming International Congress for Ataxia Research. The conference will take place from 1st-4th November 2022 in Dallas, Texas, USA.
    • 18 Sep 2022 Results reporting PD response and treatment-emergent adverse events data presented at the 26th International Congress of Parkinson's Disease and Movement Disorders
    • 02 Jun 2022 According to a Larimar Therapeutics media release, Dr. Des Rosiers will present the results of collaborative studies with Larimar that analyzed the lipidomic profiles of samples from healthy individuals and from patients with Friedreich's ataxia that were untreated or treated with CTI-1601 during this trial in XXIV World Congress International Society for Heart Research, 2022.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top